Tirzepatide

01 · What it is

Tirzepatide has the larger effect on weight and the smaller body of hard-outcome evidence, and both halves of that sentence matter.

The weight and glycaemic data are the strongest in the class, including a randomised head-to-head trial against semaglutide in obesity without diabetes ¹⁸ and an earlier head-to-head in type 2 diabetes ². What tirzepatide did not have, at the point its cardiovascular outcome trial’s design paper was published, was a completed cardiovascular outcome trial: the authors of that paper stated plainly that the cardiovascular safety and efficacy of tirzepatide have not been definitively assessed in a cardiovascular outcomes trial, and described SURPASS-CVOT as fully recruited and ongoing ⁸.

This guide located the SURPASS-CVOT design and baseline paper but not its results publication. That is a limitation of this search rather than a statement that no result exists; it is flagged for verification below and should be checked against the current literature before this guide is relied on for that point.

What it is. Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors — a single molecule acting at two incretin receptors rather than one ^3,5. A 2022 review described its effect on glycaemic control and body weight as unprecedented for a single agent, with SURPASS 1–5 reporting HbA1c reductions of 1.24 to 2.58% and body-weight reductions of 5.4 to 11.7 kg ⁵.

The uncomfortable number is not in the trials. In the observational comparison with semaglutide, follow-up ended through discontinuation for 5,140 patients — 55.9% of the cohort ¹¹. Whatever the randomised trials establish about efficacy under protocol, more than half of a real-world population stopped.

02 · Evidence at a glance

Evidence grade

Approved Pharma — extensive randomised phase 3 evidence

What it is

A dual GIP and GLP-1 receptor agonist ^3,5

Class effect size

HbA1c 1.24–2.58%; body weight 5.4–11.7 kg across SURPASS 1–5; described as unprecedented for a single agent ⁵

SURPASS-1

HbA1c fell 1.87% (5 mg), 1.89% (10 mg) and 2.07% (15 mg) versus +0.04% on placebo ¹

SURPASS-2

Randomised head-to-head against semaglutide in type 2 diabetes ²

SURPASS-4

Versus insulin glargine in type 2 diabetes at increased cardiovascular risk, with a stated focus on cardiovascular safety ³

SURPASS-CVOT

Versus dulaglutide, for major adverse cardiovascular events; design paper states CV safety and efficacy “have not been definitively assessed”; trial fully recruited and ongoing ⁸

SURMOUNT-1

Once-weekly tirzepatide for obesity ⁴; later analysis addressed diabetes prevention ¹⁵; body-composition substudy ¹⁷

SURMOUNT-3

After intensive lifestyle intervention ⁷; quality-of-life analysis ¹⁹

SURMOUNT-4

Continued treatment for maintenance of weight reduction ⁹

SURMOUNT-CN

52-week weight change −13.6% (95% CI −15.8 to −11.4) at 10 mg and −17.5% (95% CI −19.7 to −15.3) at 15 mg versus −2.3% on placebo ¹⁰

SURMOUNT-5

Randomised head-to-head versus semaglutide in obesity without type 2 diabetes ¹⁸

SUMMIT

Heart failure with preserved ejection fraction and obesity ¹⁴

SURMOUNT-OSA

Obstructive sleep apnoea and obesity ¹²

Real-world discontinuation

55.9% (5,140 patients) ended follow-up by discontinuation in the observational comparison ¹¹

Regulatory status

Prescription-only medicine

03 · Mechanism of action

Two receptors, one molecule

Tirzepatide agonises both the GIP receptor and the GLP-1 receptor ^3,5. GIP and GLP-1 are the two principal incretin hormones; the design premise is that engaging both produces effects that a selective GLP-1 agonist does not.

The premise is testable and was tested, which is the part worth noting. SURPASS-2 and SURMOUNT-5 put the dual agonist against a selective GLP-1 agonist in randomised comparisons ^2,18, so the question of whether adding GIP agonism buys anything was not left to argument.

What the receptor combination is claimed to add

The 2022 review by Nauck and D’Alessio frames the compound as producing glycaemic and weight effects unprecedented for a single agent, across five phase 3 trials ⁵. A drug-overview paper from the following year summarises the same programme and describes adverse effects as comparable to GLP-1 receptor agonists ⁶.

That second claim — comparable adverse effects to the single-receptor class — is a summary statement in an overview article, not a formal safety comparison, and is reported here as such.

Where the mechanism has been tested beyond glycaemia

The trial programme extends into heart failure with preserved ejection fraction ¹⁴, obstructive sleep apnoea ¹², body composition ¹⁷, and progression to type 2 diabetes ¹⁵.

Sleep apnoea is the interesting case. Obstructive sleep apnoea has excess adiposity as an aetiologic risk factor ¹², so a weight effect has a plausible route to a respiratory endpoint. That is a mechanism operating through a change in body mass rather than a direct receptor effect on the airway, and the distinction matters for how far the result generalises.

04 · Key research findings

Glycaemic control in type 2 diabetes

SURPASS-1, 2021. A double-blind randomised phase 3 trial. Mean HbA1c fell by 1.87% at 5 mg, 1.89% at 10 mg and 2.07% at 15 mg, against +0.04% on placebo ¹.

SURPASS-2, 2021. Once-weekly tirzepatide compared with semaglutide in type 2 diabetes, in a trial whose premise was that the relative efficacy and safety of the two were unknown ².

SURPASS-4, 2021. Versus insulin glargine in type 2 diabetes with high cardiovascular risk inadequately controlled on oral agents, with a stated special focus on cardiovascular safety ³.

Programme review, 2022. SURPASS 1–5 reduced HbA1c by 1.24 to 2.58% and body weight by 5.4 to 11.7 kg, described as unprecedented for a single agent ⁵. A 2023 overview covers the same five trials ⁶.

The synthesis across this system: the glycaemic evidence is randomised, replicated, dose-ranged and active-comparator-controlled, which is about as complete as a glycaemic evidence base gets.

Body weight

SURMOUNT-1, 2022. Once-weekly tirzepatide for the treatment of obesity, reporting improvements in all prespecified cardiometabolic measures, with gastrointestinal adverse events most common and mostly mild to moderate, occurring primarily during dose escalation ⁴.

SURMOUNT-3, 2023. Tirzepatide after a successful intensive lifestyle intervention, addressing an effect the authors state was unknown ⁷. A later analysis reported health-related quality of life in the same randomised population and subgroups ¹⁹.

SURMOUNT-4, 2024. Continued treatment for maintenance of weight reduction, opening on the statement that the effect of continued treatment on maintaining initial reduction was unknown ⁹.

SURMOUNT-CN, 2024. In Chinese adults with obesity, 52-week mean weight change was −13.6% (95% CI −15.8 to −11.4) at 10 mg and −17.5% (95% CI −19.7 to −15.3) at 15 mg, versus −2.3% on placebo; the 10 mg-versus-placebo difference was −11.3% (95% CI −14.3 to −8.3) ¹⁰.

SURMOUNT-1 extended analysis, 2025. Obesity treatment and diabetes prevention, following an earlier analysis that had reported substantial and sustained weight reduction ¹⁵.

Body composition, 2025. A substudy of SURMOUNT-1 assessing composition changes overall and, post hoc, in subgroups ¹⁷.

SURMOUNT-5, 2025. Tirzepatide compared with semaglutide for the treatment of obesity in adults without type 2 diabetes — a randomised trial addressing a comparison the authors state was unknown ¹⁸.

The synthesis: the weight literature is unusually complete in design — placebo-controlled, maintenance-controlled, lifestyle-controlled, geographically replicated, and finally head-to-head-controlled against the nearest alternative. Very few compounds in this project have all five.

Cardiovascular and cardiopulmonary endpoints

SURPASS-CVOT design, 2024. A comparison against dulaglutide for major adverse cardiovascular events in type 2 diabetes with atherosclerotic cardiovascular disease. The design paper states that cardiovascular safety and efficacy had not been definitively assessed in a cardiovascular outcomes trial, that the trial was fully recruited and ongoing, and that it would provide definitive evidence ⁸.

SURMOUNT-OSA, 2024. Obstructive sleep apnoea and obesity, framed on the association between disordered breathing in sleep and major cardiovascular complications ¹². A 2024 commentary offers a perspective on the effect on hypoxic burden and describes its own contribution as indirect evidence of cardiovascular risk reduction ¹³.

That commentary is explicit about being indirect, and this guide keeps that word. An effect on hypoxic burden is not an effect on cardiovascular events; treating the first as the second is the biomarker-for-outcome substitution this project flags wherever it appears.

SUMMIT, 2025. Heart failure with preserved ejection fraction and obesity, opening on the observation that data were lacking for this population ¹⁴.

The synthesis: cardiovascular evidence for tirzepatide is a mixture of a dedicated outcome trial whose design is published, a heart-failure trial with a symptomatic and functional focus, and a sleep trial whose cardiovascular relevance its own commentators call indirect. This is a materially different footing from a completed event-driven outcome trial.

Comparative and real-world data

Observational comparison, 2024. Tirzepatide versus semaglutide for weight in adults with overweight or obesity, on the stated basis that head-to-head data in that population were not then available. Follow-up ended by discontinuation for 5,140 patients, 55.9% ¹¹.

Real-world review, 2025. Utilisation, clinical and comparative effectiveness, and adverse effects of newer GLP-1 receptor agonist weight-loss therapies, covering liraglutide, semaglutide and tirzepatide ¹⁶.

STEER, 2026. A real-world assessment of semaglutide versus tirzepatide for major adverse cardiovascular events among patients with overweight or obesity and established atherosclerotic cardiovascular disease without diabetes ²⁰.

The synthesis: the comparative literature is observational except for SURPASS-2 and SURMOUNT-5, and the observational studies carry a discontinuation rate above half. Effectiveness in a population where most people stop is a different quantity from efficacy in a population that continues.

05 · Evidence overview

06 · Safety profile

This section reports the existence and structure of the safety literature. It does not enumerate adverse effects, contraindications, warnings or monitoring requirements, which are matters for the product label and for prescribing clinicians. This guide has read abstracts rather than full trial safety reports.

Animal data. No preclinical toxicology paper was retrieved in this search. The regulatory programme necessarily rests on one; it is simply not among the records examined here.

Human data. SURMOUNT-1 reported that the most common adverse events were gastrointestinal, mostly mild to moderate, occurring primarily during dose escalation ⁴; SURMOUNT-3 reported the same pattern ⁷. SURPASS-4 was designed with a special focus on cardiovascular safety ³. A 2023 overview describes adverse effects as comparable to GLP-1 receptor agonists ⁶. Real-world adverse-effect evidence for the class exists as its own literature ¹⁶.

The dose-escalation detail is the useful one. An adverse-event pattern concentrated in the titration phase is a pattern produced by a titration schedule — which exists in trials and in prescribing, and does not exist by default anywhere else.

What is genuinely unknown. Three things, stated separately.

The cardiovascular outcome question, as located here. The design paper for SURPASS-CVOT states that cardiovascular safety and efficacy had not been definitively assessed in an outcomes trial ⁸. This guide did not locate the results publication. Until that is checked, the honest position is that this guide cannot report a cardiovascular outcome result for tirzepatide, and does not.

Everything outside prescribed conditions. All evidence above was generated with a characterised product, at defined doses on a defined titration schedule, in selected participants under monitoring. No published analysis located here examines the identity, purity, concentration or contamination status of any tirzepatide-labelled material obtained outside a pharmacy supply chain.

What discontinuation represents. More than half of the observational cohort stopped ¹¹. The published abstract does not, in what was read here, resolve how much of that is tolerability, cost, access or something else — and that is itself the point: a number that large is unexplained in the material examined.

07 · US regulatory status

Current as of 7 September 2026. Tirzepatide is a prescription-only medicine, approved and marketed in the United States and other jurisdictions ⁶. It is not a controlled substance.

This guide has not consulted FDA or EMA approval records, product labels or review documents, and makes no statement about specific approved indications, dosing, contraindications or warnings.

Supplying or obtaining prescription drugs outside a lawful prescription is unlawful in the United States and in most other jurisdictions.

Under the World Anti-Doping Code, competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. This guide did not locate a completed cardiovascular outcome trial result. The design and baseline paper is cited ⁸ and states the trial was ongoing at that time. This is flagged for primary-source verification and is the single most important open item in this guide.
2. The comparative evidence is mostly observational. Only SURPASS-2 and SURMOUNT-5 are randomised head-to-head trials ^2,18. The rest is propensity-matched or database work ^11,20, which reduces confounding without eliminating it.
3. Real-world discontinuation exceeds half ¹¹. Any effectiveness figure drawn from a population in which 55.9% stopped describes something different from trial efficacy, and the abstracts read here do not explain the attrition.
4. Trial populations are selected. SURMOUNT-3 enrolled people who had already succeeded at an intensive lifestyle intervention ⁷; SURMOUNT-4 enrolled people who had already responded ⁹; SUMMIT enrolled a heart-failure population ¹⁴. Each result belongs to the population that produced it.
5. The sleep apnoea cardiovascular inference is indirect and says so ¹³. Hypoxic burden is a physiological measure, not an event count.
6. Post-hoc subgroup analysis appears in the body-composition substudy ¹⁷, which the authors label as such.
7. Sponsor involvement runs throughout. SURMOUNT-1, SURMOUNT-5 and SURMOUNT-OSA are identified in their abstracts as funded by Eli Lilly ^4,12,18, as is normal for a registration programme, with recurring investigator groups across trials.
8. No preclinical toxicology was retrieved in this search, so this guide reports no animal safety data at all.
9. Fewer than twenty-five of roughly 896 records were examined on this search, weighted toward phase 3 trials.
10. This guide has read abstracts, not full texts, for every source cited.
11. Nothing is known about non-pharmacy material. No published analysis located here has examined any tirzepatide-labelled product obtained outside a regulated supply chain.

09 · Legal and regulatory appendix

This appendix applies to every compound in this family and is reproduced in each guide.

Prescription status. Tirzepatide is a prescription-only medicine wherever it is approved. Obtaining, supplying, possessing for supply, importing or administering prescription medicines outside a lawful prescription is unlawful in the United States and in most other jurisdictions. This guide does not describe how to obtain the compound and takes no position on any supplier.

Compounded and unapproved preparations. Preparations labelled as tirzepatide that are not approved products have no established relationship to the material used in the trials cited here. This guide located no published analysis of the identity, purity, concentration, sterility or contamination status of any such preparation. Nothing in the trial evidence described above should be read as applying to them.

Research-use labelling. Material labelled for laboratory research use is not manufactured, tested, or released to the standards applied to medicines intended for people, and such labelling does not make administration lawful or safe.

What this guide is. A description of the published peer-reviewed literature, written for readers who want to understand the state of the evidence. It is not medical advice, not a recommendation, not an endorsement, and not a substitute for a clinician who can assess an individual situation.

Editorial position. Arkham Labs publishes independently and earns through disclosed referral links. That commercial relationship is disclosed on every page carrying such a link and on the editorial standards page. It does not alter what the evidence says.

10 · References

1. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143–155.

   PMID 34186022 ↗

2. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021 Aug 5;385(6):503–515.

   PMID 34170647 ↗

3. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811–1824.

   PMID 34672967 ↗

4. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022 Jul 21;387(3):205–216.

   PMID 35658024 ↗

5. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022 Sep 1;21(1):169. Review.

   PMID 36050763 ↗

6. Gettman L. New drug: tirzepatide (Mounjaro). Sr Care Pharm. 2023 Feb 1;38(2):50–62.

   PMID 36751934 ↗

7. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023 Nov;29(11):2909–2918.

   PMID 37840095 ↗

8. Nicholls SJ, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Zoungas S, Basile J, Bartee A, Miller D, Nishiyama H, Pavo I, Weerakkody G, Wiese RJ, D’Alessio D; SURPASS-CVOT Investigators. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024 Jan;267:1–11.

   PMID 37758044 ↗

9. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024 Jan 2;331(1):38–48.

   PMID 38078870 ↗

10. Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, Wang R, Yuan Y, Li X. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024 Aug 20;332(7):551–560.

    PMID 38819983 ↗

11. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024 Sep 1;184(9):1056–1064.

    PMID 38976257 ↗

12. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024 Oct 3;391(13):1193–1205.

    PMID 38912654 ↗

13. Beccuti G, Bioletto F, Parasiliti-Caprino M, Benso A, Ghigo E, Cicolin A, Broglio F. Estimating cardiovascular benefits of tirzepatide in sleep apnea and obesity: insight from the SURMOUNT-OSA trials. Curr Obes Rep. 2024 Dec;13(4):739–742. Review.

    PMID 39378016 ↗

14. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025 Jan 30;392(5):427–437.

    PMID 39555826 ↗

15. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025 Mar 6;392(10):958–971.

    PMID 39536238 ↗

16. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2:66–88. Review.

    PMID 40196933 ↗

17. Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, Stefanski A, Griffin R. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025 May;27(5):2720–2729.

    PMID 39996356 ↗

18. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025 Jul 3;393(1):26–36.

    PMID 40353578 ↗

19. Gibble TH, Cao D, Forrester T, Fraseur Brumm J, Chao AM. Tirzepatide and health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-3 phase 3 randomized trial. Diabetes Obes Metab. 2025 Aug;27(8):4268–4279.

    PMID 40365662 ↗

20. Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh BÓ, Stensen S, Ozer K. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes Obes Metab. 2026 Mar;28(3):2403–2415.

    PMID 41491349 ↗